Arcadia Biosciences (RKDA)
(Delayed Data from NSDQ)
$4.45 USD
+0.11 (2.53%)
Updated Aug 5, 2025 03:46 PM ET
After-Market: $4.50 +0.05 (1.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RKDA 4.45 +0.11(2.53%)
Will RKDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RKDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RKDA
Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105%
Arcadia Biosciences' Q3 Earnings Miss Estimates, Sales Increase Y/Y
RKDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
GrowGeneration Earnings Miss Estimates in Q3, Revenues Dip Y/Y
Arcadia Biosciences (RKDA) Reports Q3 Loss, Tops Revenue Estimates
Hydrofarm Holdings Group, Inc. (HYFM) Reports Q3 Loss, Lags Revenue Estimates
Other News for RKDA
Arcadia Biosciences Faces Payment Default from Above Food
Arcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call Transcript
Arcadia Biosciences Reports Strong Q1 2025 Results
Arcadia Biosciences (RKDA) Gets a Buy from Lake Street
Arcadia Biosciences Reports Strong Growth Amid Challenges